Poster

Brigatinib in Japanese Patients With ALK+ NSCLC: Final Results From the Phase 2 J-ALTA Trial

Author

Toru Kumagai

Condition

Non–small cell lung cancer (NSCLC)

Drug target

ALK tyrosine kinase

Drug moa

Inhibition of ALK resistance mutations

Source url

s3://convoke-optic-posters/2024-05-10/Kumagai et al. Brigatinib in Japanese NSCLC. Final Results J-ALTA. Poster presented at ASCO 2022.pdf

8 organizations

1 product

Product

Organization

National Cancer Center Hospital East, Kashiwa, Japan

Organization

National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan

Organization

Wakayama Medical University, Wakayama, Japan

Organization

Takeda Development Center Americas, Inc., Lexington, MA, USA

Organization

Osaka International Cancer Institute, Osaka, Japan

Organization

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan

Organization

Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Organization

Takeda Pharmaceutical Company Limited, Osaka, Japan